Skip to main content
. 2010 Aug;70(2):171–179. doi: 10.1111/j.1365-2125.2010.03696.x

Figure 2.

Figure 2

A) Symptom resolution was similar between mosapride and placebo after 4 weeks of treatment in all enrolled patients (n= 96). B) Sub-group analysis for those with pre-treatment scores >18 (n= 48) revealed mosapride was more effective than placebo in symptomatically severe patients. Data are expressed as mean ± SEM. Abbreviations: ITT, intention to treat; PP, per protocol. Mosapride (Inline graphic); Placebo (□)